Abstract
Purinergic signalling is involved in the control of vascular tone and remodelling. Endothelial cells release purines and pyrimidines in response to changes in blood flow (evoking shear stress) and hypoxia. They then act on P2Y, P2X and P1 receptors on endothelial cells leading to release of EDRF mediated by nitric oxide and prostaglandins and EDHF, resulting in vasodilatation. The therapeutic potential of purinergic compounds for the treatment of vascular diseases, including hypertension, ischaemia, atherosclerosis, migraine and coronary artery and diabetic vascular disease as well as vasospasm is discussed.
Keywords: Purinoceptors, nitric oxide, ATP, angiogenesis, atherosclerosis, hypertension, ischaemia, migraine.
Current Vascular Pharmacology
Title:Purinergic Signalling and Endothelium
Volume: 14 Issue: 2
Author(s): Geoffrey Burnstock
Affiliation:
Keywords: Purinoceptors, nitric oxide, ATP, angiogenesis, atherosclerosis, hypertension, ischaemia, migraine.
Abstract: Purinergic signalling is involved in the control of vascular tone and remodelling. Endothelial cells release purines and pyrimidines in response to changes in blood flow (evoking shear stress) and hypoxia. They then act on P2Y, P2X and P1 receptors on endothelial cells leading to release of EDRF mediated by nitric oxide and prostaglandins and EDHF, resulting in vasodilatation. The therapeutic potential of purinergic compounds for the treatment of vascular diseases, including hypertension, ischaemia, atherosclerosis, migraine and coronary artery and diabetic vascular disease as well as vasospasm is discussed.
Export Options
About this article
Cite this article as:
Burnstock Geoffrey, Purinergic Signalling and Endothelium, Current Vascular Pharmacology 2016; 14 (2) . https://dx.doi.org/10.2174/1570161114666151202204948
DOI https://dx.doi.org/10.2174/1570161114666151202204948 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
COX-2: Friend or Foe?
Current Pharmaceutical Design Averrhoa bilimbi L. leaf Aqueous Extract Modulates both Cardiac Contractility and Frequency in the Guinea-pig Atrium by the Activation of Muscarinic Receptors
Letters in Drug Design & Discovery Prodrug Strategies for Antihypertensives
Current Topics in Medicinal Chemistry Pharmacokinetics and Acute Toxicity of a Histone Deacetylase Inhibitor, Scriptaid, and its Neuroprotective Effects in Mice After Intracranial Hemorrhage
CNS & Neurological Disorders - Drug Targets Curcumin Activates Erythrocyte Membrane Acetylcholinesterase
Letters in Drug Design & Discovery Purification and Kinetics of Bovine Kidney Cortex Glutathione Reductase
Protein & Peptide Letters Determination of Interchangeability of Different Brands of Diclofenac Sodium Sustained Release Tablets in Healthy Subjects Using Pharmacokinetic End Points
Letters in Drug Design & Discovery Ca2+ Signalling in Damaged Endothelium: Do Connexin Hemichannels Aid in Filling the Gap?
Current Drug Therapy cGMP Signaling, Phosphodiesterases and Major Depressive Disorder
Current Neuropharmacology Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
CNS & Neurological Disorders - Drug Targets Diuretics: From Classical Carbonic Anhydrase Inhibitors to Novel Applications of the Sulfonamides
Current Pharmaceutical Design Counteracting Oxidative Stress in Pregnancy through Modulation of Maternal Micronutrients and Omega-3 Fatty Acids
Current Medicinal Chemistry Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets Editorial (Oxidative Stress in the Vascular Wall: A Useful Physiological Process or a Therapeutic Target in Vascular Disease?)
Recent Patents on Cardiovascular Drug Discovery Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry Prevention of Non-communicable Diseases by Balanced Nutrition: Population- specific Effective Public Health Approaches in Developing Countries
Current Diabetes Reviews Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design